Literature DB >> 15846581

Overcoming the challenge of patient compliance with iron chelation therapy.

M D Cappellini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15846581     DOI： 10.1053/j.seminhematol.2005.01.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  10 in total

Review 1.  Deferasirox for managing iron overload in people with thalassaemia.

Authors:  Claudia Bollig; Lisa K Schell; Gerta Rücker; Roman Allert; Edith Motschall; Charlotte M Niemeyer; Dirk Bassler; Joerg J Meerpohl
Journal:  Cochrane Database Syst Rev       Date:  2017-08-15

Review 2.  Deferasirox for managing iron overload in people with myelodysplastic syndrome.

Authors:  Joerg J Meerpohl; Lisa K Schell; Gerta Rücker; Nigel Fleeman; Edith Motschall; Charlotte M Niemeyer; Dirk Bassler
Journal:  Cochrane Database Syst Rev       Date:  2014-10-28

3.  Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.

Authors:  Robert W Grady; Renzo Galanello; Rachel E Randolph; Dorothy A Kleinert; Carlo Dessi; Patricia J Giardina
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

4.  Challenges of adherence and persistence with iron chelation therapy.

Authors:  John B Porter; Michael Evangeli; Amal El-Beshlawy
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

5.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17

6.  Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.

Authors:  Ellen B Fung; Paul R Harmatz; Meredith Milet; Vinod Balasa; Samir K Ballas; James F Casella; Lee Hilliard; Abdullah Kutlar; Kenneth L McClain; Nancy F Olivieri; John B Porter; Elliott P Vichinsky
Journal:  Transfusion       Date:  2008-05-29       Impact factor: 3.157

7.  Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.

Authors:  Norbert Gattermann; Andrea Jarisch; Rudolf Schlag; Klaus Blumenstengel; Mariele Goebeler; Matthias Groschek; Christoph Losem; Maria Procaccianti; Alexia Junkes; Oliver Leismann; Ulrich Germing
Journal:  Eur J Haematol       Date:  2011-11-24       Impact factor: 2.997

Review 8.  β-Thalassemia Intermedia: A Bird's-Eye View.

Authors:  Anthony Haddad; Paul Tyan; Amr Radwan; Naji Mallat; Ali Taher
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

Review 9.  Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.

Authors:  Jong Wook Lee
Journal:  Int J Hematol       Date:  2008-07-05       Impact factor: 2.490

10.  Deferasirox: appraisal of safety and efficacy in long-term therapy.

Authors:  Preeti Chaudhary; Vinod Pullarkat
Journal:  J Blood Med       Date:  2013-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.